At our recent Snack and Learn, Daphne Franks, an advocate against predatory marriage, shared a personal story about the importance of stronger laws to protect vulnerable adults with serious health conditions such as #dementia. The session highlighted how existing legal frameworks may not always protect those who are at risk. We’re proud to support patients and families through programs like Magnolia Purpose in Planning to help those in the Alzheimer’s disease and dementia community avoid difficult situations like Daphne’s. Thank you, Daphne, and all who joined us. #LifeAtEisai #AlzheimersDisease #EndAlz
Eisai US
Pharmaceutical Manufacturing
Nutley, NJ 138,856 followers
Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines: https://bit.ly/3dkY
About us
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.
- Website
-
http://us.eisai.com
External link for Eisai US
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Nutley, NJ
- Type
- Public Company
- Founded
- 1995
- Specialties
- Neurology, Gastroenterology, Alzheimer's disease, Oncology, Epilepsy, Insomnia, Metastatic breast cancer, renal cell carcinoma, hepatocellular carcinoma, dementia, and endometrial cancer
Locations
-
Primary
200 Metro Blvd.
Nutley, NJ 07110, US
-
Employees at Eisai US
Updates
-
We were honored to attend the Prevent Cancer Foundation’s 40th Anniversary Gala, celebrating four decades of impact in cancer prevention and early detection. This milestone event highlighted our shared mission and collective dedication to raising awareness and advancing health outcomes. We look forward to continuing this vital work. #LifeAtEisai
-
-
Thanks to everyone who visited the Spot Her truck in Nashville and Phoenix! It was incredible to connect with so many of you and raise awareness about the signs of #endometrialcancer (EC) - together. Visit the Spot Her website to learn more about EC: https://bit.ly/4hOM4DY #SpotHerForEC
-
-
Hispanic people are almost twice as likely to develop liver cancer than non-Hispanic whites. With #LiverCancerAwarenessMonth and #HispanicHeritageMonth overlapping, now is the time to shed light on how this disease impacts the Hispanic community. Check out our One Liver to Love initiative which provides educational resources and support services to people living with liver cancer: https://bit.ly/4pOYsZV
-
-
Our team in Raleigh was honored to host Congresswoman Deborah Ross for a thoughtful discussion on supply chain policy and the regulatory and legislative solutions needed to support pharmaceutical manufacturing and distribution. Thank you, Representative Ross, for your leadership and engagement. #LifeAtEisai
-
-
The #ESMO25 Congress brings together researchers, clinicians, and advocates dedicated to transforming cancer care. We look forward to presenting clinical data, including in endometrial carcinoma and renal cell carcinoma, in Berlin. Our research portfolio includes long-term follow-up insights and innovative therapeutic approaches. We're excited to contribute to the scientific dialogue that drives progress for patients worldwide. Rooted in our human health care philosophy, everything we do centers on working to improve outcomes for those who need it most. Learn more about our #ESMO25 presentations by reading our press release: bit.ly/EisaiESMO2025
-
-
It’s estimated that nearly 317,000 women will be diagnosed with invasive breast cancer in 2025. While we can’t control every factor, understanding your individual risk can empower you to make proactive choices for your health. This includes knowing your family’s medical history, as genetics can play a significant role. Early detection can make all the difference. By having regular conversations with your health care provider, you can create a personalized plan for prevention and screening. During #BreastCancerAwarenessMonth, take charge of your well-being by scheduling a check-up to discuss your risk factors and screening options today.
-
“Patients first and families first,” that’s the heart of our human health care mission. Hear from KATSUYA HARUNA, Executive Vice President, US Business Operations, as he shares how our hhc mission drives everything we do at Eisai. #LifeAtEisai
-
The SHARE Cancer Support Annual Gala: A Second Helping of Life was a profound reminder of what’s possible when we come together to support people impacted by cancer. The evening honored the unwavering commitment of those who help uplift the #oncology community and work tirelessly to advance patient care. #LifeatEisai
-
-
Team Eisai proudly participated in the Race to End Women’s Cancer to help raise awareness for people impacted by gynecologic cancers. Every step taken was dedicated to supporting patients, survivors and their families. Special thanks to the Foundation for Women’s Cancer for organizing this meaningful event.
-